|
|
Résultats pour
 brevets
1.
|
IMMUNITY AND PROTECTION OF SARS-COV-2 DNA AND PROTEIN VACCINE
| Numéro d'application |
18254373 |
| Statut |
En instance |
| Date de dépôt |
2021-11-24 |
| Date de la première publication |
2024-01-18 |
| Propriétaire |
INSTITUTE OF MEDICAL BIOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES & PEKING UNION MEDICAL COLLEGE (Chine)
|
| Inventeur(s) |
- Cun, Wei
- Lu, Shan
- Li, Qihan
- Xiao, Hongjian
- Bi, Yanwei
- Li, Yuzhong
- Liu, Xiaojuan
- Li, Zhihua
|
Abrégé
Provided are a DNA vaccine against SARS-CoV-2 virus infection in a subject which comprises a codon optimized polynucleotide sequence encoding a polypeptide of the SARS-CoV-2 virus. Also provided are a vaccine combination against SARS-CoV-2 vims infection, which comprises said DNA vaccine and an antigen peptide vaccine. The vaccine combination is able to confer a full protection against the SARS-CoV-2 vims infection in NHP studies.
Classes IPC ?
- A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
- C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
- A61P 31/14 - Antiviraux pour le traitement des virus ARN
|
2.
|
METHOD FOR PREPARING NOVEL CORONAVIRUS VACCINE AND METHOD FOR EVALUATING EFFECTIVENESS THEREOF
| Numéro d'application |
CN2021143090 |
| Numéro de publication |
2022/143901 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2021-12-30 |
| Date de publication |
2022-07-07 |
| Propriétaire |
INSTITUTE OF MEDICAL BIOLOGY CHINESE ACADEMY OF MEDICAL SCIENCES & PEKING UNION MEDICAL COLLEGE (Chine)
|
| Inventeur(s) |
- Li, Qihan
- Fan, Shengtao
- Liu, Longding
- Xie, Zhongping
- Chen, Hongbo
- He, Zhanlong
- Long, Runxiang
- Zhao, Heng
- Zheng, Huiwen
- Wang, Lichun
- Yu, Li
- Li, Jing
- Guo, Lei
- Liao, Yun
- Li, Dandan
- Jiang, Guorun
- Zhang, Ying
- Xu, Xingli
- Yang, Fengmei
- Pu, Jing
- Che, Yanchun
- Zhao, Zhimei
- Xu, Mingjue
|
Abrégé
Provided in the present invention are a method for preparing a novel coronavirus vaccine and a method for evaluating the effectiveness thereof. The novel coronavirus vaccine is an inactivated vaccine in which a part of a virus membrane is split so as to expose a nucleocapsid N antigen. The vaccine strain is inactivated twice during preparation, the first inactivation is carried out by means of using formaldehyde (HCHO), and then the second inactivation is carried out by means of using β-propiolactone (BPL). The method for evaluating the novel coronavirus vaccine comprises a plurality of detection methods comprising antibody neutralization, Elisa antibody determination and specific CTL detection.
Classes IPC ?
- A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
- A61P 31/14 - Antiviraux pour le traitement des virus ARN
- A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
- G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
|
3.
|
IMMUNITY AND PROTECTION OF SARS-COV-2 DNA AND PROTEIN VACCINE
| Numéro d'application |
CN2021132703 |
| Numéro de publication |
2022/111511 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2021-11-24 |
| Date de publication |
2022-06-02 |
| Propriétaire |
- INSTITUTE OF MEDICAL BIOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES & PEKING UNION MEDICAL COLLEGE (Chine)
- LU, Shan (USA)
|
| Inventeur(s) |
- Cun, Wei
- Lu, Shan
- Li, Qihan
- Xiao, Hongjian
- Bi, Yanwei
- Li, Yuzhong
|
Abrégé
Provided are a DNA vaccine against SARS-CoV-2 virus infection in a subject which comprises a codon optimized polynucleotide sequence encoding a polypeptide of the SARS-CoV-2 virus. Also provided are a vaccine combination against SARS-CoV-2 virus infection, which comprises said DNA vaccine and an antigen peptide vaccine. The vaccine combination is able to confer a full protection against the SARS-CoV-2 virus infection in NHP studies.
Classes IPC ?
- C12N 15/50 - Coronaviridae, p. ex. virus de la bronchite infectieuse, virus de la gastro-entérite transmissible
- A61K 39/225 - Virus de la gastro-entérite transmissible du porc
- A61P 31/14 - Antiviraux pour le traitement des virus ARN
- C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
- C07K 14/17 - Virus de la gastro-entérite transmissible du porc
- A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
|
|